Kornimate/medical-research-clean huggingface dataset:
dietary fatty acids, ppar activated genes, and chd

Conditions: Coronary Disease; Cardiovascular Diseases; Heart Diseases; Myocardial Infarction

Summary: to examine the relationship between genetic and dietary factors that modify the risk of coronary heart disease (chd).

background: coronary heart disease (chd) is the major cause of death in most industrialized and developing countries. links between genetic and dietary factors that modify the risk of chd should give fundamental insight into its causes and improve population-based chd prevention strategies. design narrative: the study will identify genes that modulate the association between dietary fatty acids (fas) and myocardial infarction (mi). the study uses dna samples obtained during a population-based, case-control study in costa rica of 2,150 subjects who experienced myocardial infarctions and 2,150 matched controls. biochemical measurements, dietary data, and general information are available for this population. one unique aspect of the study is that adipose tissue biomarkers of polyunsaturated fas will be used to evaluate dietary exposure variables. adipose tissue biomarkers (i.e., alpha-linolenic and linoleic acid) are very good indicators of intake in this population. furthermore, this study showed that increased levels of these biomarkers in adipose tissue are strongly associated with decreased risk of mi, whereas an increase in 18:2 trans fas increase the risk of mi. gene-diet association studies and a "candidate pathway" approach will be used to elucidate genetic mechanisms that link risk of mi with exposure to polyunsaturated fas \[including cis and trans isomers of linoleic acid (n-6), and alpha-linolenic acid (n-3)\]. the focus will be on peroxisome proliferator-activated receptor (ppar) genes, and ppar-regulated genes, that are involved in vascular inflammation. among controls, the investigators will examine whether genetic and dietary factors independently affect biochemical markers (phenotypes) of the proposed genes. they will also test whether these phenotypes are more clearly identified when genetic and dietary factors are examined together. because polyunsaturated fas are important as activators of ppars and their capacity to regulate gene expression at the level of transcription, this metabolic system is a suitable candidate for the study.

Eligibility criteria:
first acute mi living in catchment area randomly selected controls matched for age sex and area of residence
nurse amie for echo show: randomized control trial

Conditions: Metastatic Breast Cancer

Summary: the nurse amie platform has been modified for use as an amazon alexa skill for use on the echo show device. the investigators will recruit women receiving treatment for metastatic breast cancer and randomize patients to receive standard treatment (control) or the nurse amie for echo show program. nurse amie is a supportive care program for women undergoing chemotherapy and helps manage symptoms. the investigators will test the feasibility of using the nurse amie program as well as its effectiveness at managing symptoms.

the investigators will recruit 42 mbc patients and randomize them into a partial crossover trial in which immediate treatment group participants receive the nurse amie intervention in full for 3 months, then continue nurse amie (without navigation) for 3 months, while the delayed intervention group will not receive an intervention for 3 months, followed by receiving the nurse amie full intervention with navigation for 3 months. the primary comparisons will be between the immediate treatment and delayed treatment groups over the first 3 months. intervention. participants will all receive an amazon echo show device, wifi connection (if patients do not already have one), pedometer, and resistance bands. each day, the participant will open the nurse amie for echo show, which will result in the daily greeting. after the greeting, participants will be asked to provide a verbal rating of their symptoms (e.g., pain, sleep, fatigue, and distress). after completing the symptom survey, nurse amie will use an algorithm to discern which of the intervention modules to offer as assistance for the reported symptoms. these interventions include exercise, guided relaxation, cognitive behavioral therapy, and soothing music. these guideline-based interventions are provided as audio files or youtube-style videos. in addition, nurse amie provides a daily educational nutrition tip as well as recipes designed to be of interest to people undergoing chemotherapy. each week, the participant will receive a phone call from the study navigator. this navigator will monitor symptom ratings daily and will discuss symptoms, interventions, and step goals with the participant each week.

Eligibility criteria:
inclusion criteria: 1. female patient with metastatic breast cancer receiving care at psci 2. age: ≥18years of age 3. personal in-home wi-fi access 4. personal device capable of receiving telephone calls for weekly study facilitator check-ins 5. fluent in written and spoken english 6. sufficient vision/hearing to use the alexa echo show. exclusion criteria: 1. ecog performance status score of \>2 2. patients with significant medical or psychiatric conditions (beyond breast cancer, its treatment, and its symptoms) that in the opinion of the research team exclude the subject from participation. 3. receiving any behavioral intervention. 4. pregnant 5. cognitive impairment 6. life expectancy of less than 6 months as determined by the treating physician
pitavastatin on carotid intima-media thickness

Conditions: Hyperlipidemia; Carotid Artery Diseases

Summary: this study is aimed to analyze the effects of aggressive and conventional lipid lowering therapy with pravastatin on carotid intima-media thickness (imt) in patients with hyperlipidemia and abnormal thickening of imt.


Eligibility criteria:
inclusion criteria: * diagnosed as having hyperlipidemia * ldl-c at the time of enrollment is no less than 100 * common carotid imt is 1.1 mm and over exclusion criteria: * received or planned to receive intervention on carotid arteries during the study period * overt liver dysfunction (alt; 100 iu/l and over) * overt renal dysfunction (serum creatinine; 2.0 mg/dl and over) * receiving cyclosporin * hyperreactive to pitavastatin * during pregnancy or lactation
saline with alcohol in transurethral resection and photoselective vaporisation of the prostate

Conditions: Benign Prostatic Hypertrophy

Summary: transurethral therapy (turis / pvp) of benign prostatic hyperplasia (bph) using an ethanol-containing saline irrigating fluid, prospective detected by breath alcohol measurement.

aim was to evaluate the amount of absorbed saline irrigation fluid during transurethral therapy of benign prostatic hyperplasia (bph). we want to differentiate two different methods of the surgical therapy: the transurethral resection in saline (turis) and the photoselective vaporisation of the prostate (pvp). both methods using saline irrigation. to measure the amount of absorbed saline irrigation fluid, we added pure ethanol to the irrigation fluid resulting in am 0,02% ethanol containing saline irrigation fluid. the conventional transurethral resection of the prostate (tur) method is using electrolyte free irrigation. in the literature this method is well known for the occurence of the transurethral resection syndrome ("tur syndrome"). this is caused by absorption of electrolyte-free irrigating fluid, followed by a hyponatraemic hyperhydration, and consists of symptoms from the circulatory and nervous systems.

Eligibility criteria:
inclusion criteria: * patients in which a turis or pvp to be performed exclusion criteria: * alcoholics, * patients with severe hepatic impairment, * epilepsy, * existing metabolic acidosis.
mrx-i versus linezolid for the treatment of acute bacterial skin and skin structure infection

Conditions: Bacterial Infections

Summary: the purpose of this study is to determine whether mrx-i is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections


Eligibility criteria:
inclusion criteria: * patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (absssi) * diagnosed with cellulitis/ erysipelas, major cutaneous abscess, or wound infections exclusion criteria: * uncomplicated skin infections * severe sepsis or septic shock * absssi solely due to gram-negative pathogens * prior systemic antibiotics within 96 hours of randomization

Keywords: absssi mrx-i acute bacterial skin and skin structure infections
optimizing treatment of adhesive small bowel obstruction

Conditions: Adhesive Small Bowel Obstruction

Summary: small bowel obstruction (sbo) is one of the most common causes of serious gastrointestinal disease in the us. adhesion-related sbo (asbo) is usually treated by the placement of a nasogastric tube (ngt) to decompress the stomach, administration of intravenous (iv) fluids and observation by a surgical team. the purpose of this feasibility study is to determine the potential for implementation of treatment protocols for asbo and determine the feasibility of randomizing patients with asbo to receive or not receive ngts or water-soluble contrast (wsc). the investigators will also determine the ability to measure hrqol as a main outcome for the treatment of asbo. the studies outlined in this research program intend to address gaps in knowledge about how to determine who benefits from ngt placement, who can be managed without them, how to objectively determine when a bowel obstruction has resolved, how to reintroduce feeding to patients with asbo, what criteria should be used for hospital discharge and what role cathartics such as wsc contrast have in the management of asbo. this feasibility study will enroll a limited number of patients (n=40) who will be followed for up to 30 days.


Eligibility criteria:
inclusion criteria: 1. male or female ≥18 years of age. 2. documentation of asbo as evidenced by one or more clinical features meeting the following criteria: nausea, emesis, abdominal pain, distended abdomen ct evidence of asbo exclusion criteria: 1. pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 2. presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data. 3. unstable angina or recent myocardial infarction (mi)/stroke within 6 months 4. nonadhesive sbo 1. paralytic ileus 2. incarcerated hernia 3. fecal impaction 4. intra-abdominal malignancy early asbo within 4 weeks of a prior abdominal operation

Keywords: nasogastric tube (ngt) water-soluble contrast (wsc) adhesion-related sbo (asbo) small bowel obstruction (sbo)
impact of minimally invasive non-surgical periodontal treatment on infrabony defects

Conditions: Periodontal Intrabony Defect

Summary: fifty-two periodontitis patients (26 per group) were randomly assigned to the test (minimally invasive non-surgical therapy - minst) or the control group (quadrantwise subgingival instrumentation - q-si) npt protocols.

clinical periodontal parameters, the number of pocket sites, x-ray of the infrabony defects characteristics and a composite outcome measure (com) on the combined assessment of intrabony defect were recorded at baseline, and -3, 6- and at 12-months after treatment

Eligibility criteria:
inclusion criteria: * diagnosis of periodontitis exclusion criteria: * periodontal treatment * use of antibiotics, nsaids, and immunosuppressants during the last 6 months * pregnancy

Keywords: periodontitis
the efficacy of derotation banding on outcome measures in children with cerebral palsy

Conditions: Cerebral Palsy, Spastic

Summary: the aim of the study is to compare the conventional rehabilitation program and derotation taping applied with kinesio tex tape in addition to conventional rehabilitation in children with hemiplegic or monoplegic cerebral palsy with femoral internal rotation deformity.

conventional rehabilitation (cr) practices will be applied to the control group. conventional rehabilitation (kt) application will be applied to the study group in addition to kinesio tex tape derotation banding. with the kinesio tape application, it is aimed to provide economical, ergonomic and effective support to the patients in non-clinical times. it is aimed to evaluate the patients' balance, quality of life, performance test, spasticity level and gait quality.

Eligibility criteria:
inclusion criteria: * children with cerebral palsy aged 4-12 years with unilateral involvement who are hemiplegic or monoplegic * cases with gross motor function classification (gmfcs) level 1 or 2 * understanding simple commands and signing the consent form exclusion criteria: * presence of a static cause of femoral internal rotation deformity * situations that may prevent assessments or communication * lack of cooperation during work * presence of surgery that may affect assessments, such as joint freezing * presence of botulinum toxin administration in the last 6 months * development of an allergic reaction on the skin to the tape

Keywords: kinesio taping cerebral palsy
growth hormone's effect on the cardiovascular system

Conditions: Growth Hormone Deficiency

Summary: to evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and bmi-matched healthy population.

growth hormone deficiency (ghd) is associated with increased cardiovascular morbidity and mortality. the effects of such a deficiency include decreased exercise capacity and tolerance, impaired cardiac function, a central fat redistribution, increased peripheral arterial resistance, and an unfavorable lipid profile. these effects have been found to be reversed with appropriate replacement therapy with recombinant human growth hormone. we plan to utilize several experimental systems to further investigate the role of growth hormone (gh) in maintaining cardiovascular health. in particular, we would like to further understand the interaction of gh with plasminogen-activator-inhibitor-1 (a major activator of the fibrinolytic system) as well as the role of gh in the maintenance of vascular function.

Eligibility criteria:
inclusion criteria: * adult between the ages of 18 and 65 * documented growth hormone deficiency as defined by a peak growth hormone during a ghrh-arginine stimulation test not exceeding 9.5 ng/ml exclusion criteria: * personal history of cardiovascular disease (previous myocardial infarction or known coronary artery disease) or diagnosis of heart disease between study visits. * personal history of diabetes mellitus or development of diabetes between study visits. * initiation of an anti-cholesterol medication or anti-hypertensive between baseline and follow-up study visit. * initiation of regular tobacco use between baseline and follow-up study visit. * pregnancy or nursing * current daily use of any drug known to affect the fibrinolytic system: aspirin, aggrenox, plavix, persantine, ticlid, pletal, trental, lovenox, coumadin, agrylin, and hydroxyurea.

Keywords: growth hormone cardiovascular system
obesity-hypoventilation in metabolic syndrom patients

Conditions: Metabolic Syndrome; Obesity Hypoventilation Syndrome; Capnography

Summary: the purpose of the study is to determined the prevalence of obesity-hypoventilation syndrome in patients with metabolic syndrom.

after being informed about the study and potential risks, patient agreed to participate and undergo : a functional respiratory exploration, an arterial blood gas analyze, and a polygraphy coupled with a capnography during the same night.

Eligibility criteria:
inclusion criteria: * bmi\>30 kg/m2 * no treatment with cpap nor niv exclusion criteria: * obstructive respiratory disease * non-treated cardiac dysfunction
real world registry assessing the clinical use of the bard ultrascore forced focus pta balloon

Conditions: Peripheral Arterial Disease; Peripheral Vascular Diseases; Arterial Occlusive Diseases

Summary: the objective of this study is to assess the clinical use of the bard® ultrascore™ focused force pta balloon in a heterogeneous patient population in a real world, on-label clinical application.

the registry is a prospective, multi-center, single-arm, real-world study to assess the clinical use of the bard® ultrascore™ focused force pta balloon for the treatment of stenotic lesions of the superficial femoral artery (sfa), popliteal artery, and infra-popliteal arteries (posterior tibial, anterior tibial and peroneal arteries). follow-up for all treated subjects will be performed at hospital discharge, 30 days, and 6 and 12 months post-index procedure.

Eligibility criteria:
inclusion criteria: 1. subject must voluntarily sign and date the informed consent form (icf) prior to collection of study data or performance of study procedures. 2. subject must be either a male or non-pregnant female ≥ 21 years of age with an expected lifespan sufficient to allow for completion of all study procedures. 3. subject must be willing to comply with the protocol requirements, including the follow-up procedures. 4. subject must have a target lesion (de novo lesion or prior failed treatment) that can be treated with the ultrascore™ focused force pta balloon according to the instructions for use (ifu). only a target lesion in the sfa, popliteal, or infra-popliteal arteries (posterior tibial, anterior tibial, or peroneal arteries) may be treated for this study. 5. subject must have an above the knee (atk) or below the knee (btk) target lesion with at least one vessel run-off. 6. the target lesion must be able to be crossed using a guidewire (use of chronic total occlusion (cto) or atherectomy is allowed). exclusion criteria: 1. subjects that are to receive one or more stents as adjunctive therapy at the target lesion (bail out stenting is allowed). 2. the subject has a single target lesion that involves both atk and btk arteries. 3. the subject has a target lesion in a previously placed stent or stent graft (in-stent restenosis). 4. the subject has a lesion, which in the opinion of the investigator, would preclude safe use of the ultrascore™ focused force pta balloon. 5. the subject has a flow limiting dissection at the target lesion prior to use of the ultrascore™ focused force pta balloon. 6. the subject has acute limb ischemia. 7. the subject has been assessed rutherford category 6. 8. the subject has a known allergy or sensitivity to contrast media, which cannot be adequately pre-medicated. 9. the subject has another medical condition or is currently participating in an investigational drug or another device study that, in the opinion of the investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
immune response in the sapho syndrome

Conditions: SAPHO Syndrome

Summary: the aetiology of sapho syndrome seems to involve genetic, infectious and immunological components. the investigators examined innate and adaptative immune responses in sapho syndrome as compared with psoriatic arthritis and rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of sapho syndrome * must have bone lesions exclusion criteria: * infliximab treatment

Keywords: sapho syndrome innate immunity tnf alpha polymorphonuclear neutrophils propionibacterium acnes interleukin-8
beijing osteoporosis with neurological disorders in epigenetic changes study

Conditions: Osteoporosis，Neurological Disorders

Summary: epigenetic modification refers to the change of heritable gene expression occurring in the case of unchanged dna sequence, including dna methylation, epigenetic modification, rnas, chromatin modification, etc. the study found that osteoporosis (osteoporosis,op) with neurological disorders is very common, the risk of fracture of patients increased. it is considered that epigenetic regulation plays an important role in the occurrence and development of op with neurological disorders. in particular, the role and molecular mechanism of epigenetic modification in op with neurological disorders are not clear, and the results of clinical studies with different sample sizes are not consistent. (1) two-way continuous queues,an ambispective cohort study， namely: forward-looking queue method (2017-2027) and retrospective queue method (2007-2017) were used to understand the effect of epigenetic modification on bone mineral density, bone metabolic biochemical index, imaging index and fracture incidence of patients with neurological diseases in outpatients and wards, and to provide basis for further study. to observe the effects of epigenetic modification on cognitive function in two groups of patients (memory scale, life activity energy meter (adl) and cognitive scale (mmse) and clinical physical examination and neuropsychological test, etc., bone correlation detection (lumbar and hip bone mineral density t-score, imaging index, bone metabolic biochemical index and fracture incidence index) influence. multivariate stepwise regression analysis was performed to eliminate confounding factors, such as age, body mass index (bmi), related risk factors, and internal diseases. the patient's previous information is also analyzed; (2) to find meaningful epigenetic modification from clinical data, the molecular mechanism was studied in depth, and the imaging indexes (x-ray, ct, mri) and bone marker index (serum osteocalcin (oc), total i-type procollagen peptide (tp1np) were found in the study. type i collagen hydroxy-terminated peptide beta degradation product (β-ctx)). the relationship between the reaction epigenetic modification and cognitive function index, image and bone markers and the mechanism model were further established.


Eligibility criteria:
inclusion criteria: * normal hearing, vision, and pronunciation * dexa examination exclusion criteria: * mental retardation * blindness, deafness, and dumb * severe schizophrenia
a study of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment (stage)

Conditions: Rheumatoid Arthritis

Summary: this study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on days 1 and 15. a repeat course of i.v. treatment will be administered at weeks 24 and 26. all patients will receive 7.5mg - 25mg/week concomitant methotrexate at a stable dose. the anticipated time on study treatment is 1-2 years. target sample size is 1000.


Eligibility criteria:
inclusion criteria: * adult patients, ≥18 years of age * rheumatoid arthritis for ≥ 3 months * inadequate clinical response to methotrexate at a dose of 7.5-25mg/week for ≥ 12 weeks exclusion criteria: * rheumatic autoimmune disease or inflammatory joint disease, other than ra * prior receipt of any biologic therapy for ra * concurrent treatment with any dmard (other than methotrexate)

Keywords: anti-cd20 stage cd20 ra